 Programmed Cell Death 1 Receptor
"Programmed Cell Death 1 Receptor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inhibitory T-lymphocyte receptor that has specificity for CD274 ANTIGEN and PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN. Signaling by the receptor limits T cell proliferation and INTERFERON GAMMA synthesis. The receptor also may play an essential role in the regulatory pathway that induces PERIPHERAL TOLERANCE.
| Descriptor ID |
D061026
|
| MeSH Number(s) |
D12.776.543.750.705.222.875 D23.050.301.264.894.790 D23.101.100.894.790
|
| Concept/Terms |
Programmed Cell Death 1 Receptor- Programmed Cell Death 1 Receptor
- PD-1 Receptor
- PD 1 Receptor
- Receptor, PD-1
- CD279 Antigen
- Antigen, CD279
- PD1 Receptor
- Receptor, PD1
- Programmed Cell Death 1 Protein
- Antigens, CD279
- CD279 Antigens
|
Below are MeSH descriptors whose meaning is more general than "Programmed Cell Death 1 Receptor".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, Immunologic [D12.776.543.750.705]
- Costimulatory and Inhibitory T-Cell Receptors [D12.776.543.750.705.222]
- Programmed Cell Death 1 Receptor [D12.776.543.750.705.222.875]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, Differentiation, T-Lymphocyte [D23.050.301.264.894]
- Programmed Cell Death 1 Receptor [D23.050.301.264.894.790]
- Biomarkers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, Differentiation, T-Lymphocyte [D23.101.100.894]
- Programmed Cell Death 1 Receptor [D23.101.100.894.790]
Below are MeSH descriptors whose meaning is more specific than "Programmed Cell Death 1 Receptor".
This graph shows the total number of publications written about "Programmed Cell Death 1 Receptor" by people in this website by year, and whether "Programmed Cell Death 1 Receptor" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 2 | 2 | | 2001 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2005 | 0 | 1 | 1 | | 2007 | 0 | 4 | 4 | | 2008 | 0 | 2 | 2 | | 2009 | 0 | 2 | 2 | | 2010 | 0 | 1 | 1 | | 2011 | 0 | 3 | 3 | | 2012 | 2 | 2 | 4 | | 2013 | 3 | 2 | 5 | | 2014 | 4 | 1 | 5 | | 2015 | 3 | 5 | 8 | | 2016 | 6 | 5 | 11 | | 2017 | 4 | 4 | 8 | | 2018 | 11 | 5 | 16 | | 2019 | 13 | 5 | 18 | | 2020 | 4 | 6 | 10 | | 2021 | 7 | 3 | 10 | | 2022 | 3 | 6 | 9 | | 2023 | 0 | 7 | 7 | | 2024 | 4 | 3 | 7 | | 2025 | 4 | 11 | 15 | | 2026 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Programmed Cell Death 1 Receptor" by people in Profiles.
-
Erdem S, Haliloglu Y, Uslu IN, Houran M, Ulutabanca H, Vural A, Erturhan MB, Canatan H, Eken A. IDH1 Mutant Glioma Favors Group 3 Innate Lymphoid Cells and Is Resistant to Immune Checkpoint Expression. Inflamm Res. 2026 Apr 01; 75(1).
-
Kendra KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, Campbell KM, Carson WE, Wada DA, Plaza JA, In GK, Ikeguchi A, Hyngstrom J, Brohl AS, Chmielowski B, Khushalani NI, Markowitz J, Monroe M, Contreras CM, Bowles T, Norman K, Medina E, Gonzalez CR, Baselga-Carretero I, Garcilazo IP, Vega-Crespo A, Chen JM, Deen NNA, Patel SP, Grossmann KF, Sondak VK, Sharon E, Moon J, Wu MC, Ribas A. Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial. Nat Cancer. 2026 Feb; 7(2):272-282.
-
Park SL, Painter MM, Manne S, Alcalde V, McLaughlin M, Sullivan MA, Mathew D, Torres L, Huang YJ, Reeg DB, Douek NR, Campos T, Klapholz M, Cardenas MA, Fang V, Ngiow SF, Kc W, Goel RR, Baxter AE, Wu JE, Tan M, Berry CT, Ellebrecht CT, Huang AC, Papazian E, Liu Y, Rajasekaran K, Brody RM, Thaler ER, Basu D, Diab A, Giles JR, Wherry EJ. Tissue-resident exhausted and memory CD8+ T cells have distinct ontogeny, function and role in disease. Nat Immunol. 2026 Jan; 27(1):110-125.
-
Porter R, Bockorny B, Corr BR, Mahadevan D, Wilky BA, El-Khoueiry AB, Bullock AJ, Hafez N, Moser J, Martynova A, Stebbing J, Joshi B, Bourdelais S, Delepine C, Chand D, Wu W, Johnson B, Grossman JE, O'Day SJ, Matulonis UA, Gordon MS. Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancer. J Immunother Cancer. 2025 Dec 23; 13(12).
-
Narikawa Y, Kuramasu A, Hosonuma M, Murayama M, Funayama E, Sasaki A, Baba Y, Toyoda H, Isobe J, Tajima K, Nakashima R, Sasaki A, Maruyama Y, Yamazaki Y, Shida M, Tsurui T, Hirasawa Y, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Sambe T, Tsuji M, Wada S, Horiike A, Kobayashi S, Tsunoda T, Kobayashi S, Kobayashi H, Oguchi T, Shimane T, Kiuchi Y, Yoshimura K. Inosine shapes PD-1 blockade responses and synergizes with dual PD-1/CTLA-4 immunotherapy to enhance antitumor immunity. Cancer Immunol Immunother. 2025 Aug 19; 74(9):289.
-
Kendra KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, Campbell KM, Carson WE, Wada DA, Plaza JA, Sosman JA, In GK, Ikeguchi A, Hyngstrom J, Brohl AS, Khushalani NI, Markowitz J, Negrea G, Kasbari S, Doolittle GC, Swami U, Roberts T, Mathew BN, Medina E, Baselga-Carretero I, Gonzalez CR, Garcilazo IP, Vega-Crespo A, Chen JM, Naser Al-Deen N, Patel SP, Sharon E, Moon J, Wu MC, Ribas A. Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial. Nat Med. 2025 Nov; 31(11):3668-3674.
-
Nagaoka K, Nakanishi H, Tanaka H, Anindita J, Kawamura T, Tanaka T, Yamashita T, Kuroda A, Nomura S, Akita H, Itaka K, Kodama T, Kakimi K. Neoantigen mRNA vaccines induce progenitor-exhausted T cells that support anti-PD-1 therapy in gastric cancer with peritoneal metastasis. Gastric Cancer. 2025 09; 28(5):825-836.
-
Devi KSP, Wang E, Jaiswal A, Konieczny P, Kim TG, Nirschl CJ, Verma A, Liu Y, Milczanowski J, Christo SN, Gandolfo LC, Haitz K, Vardam TD, Wu P, King SL, Tse SW, Pradhan K, Jiang X, Tian T, Fuhlbrigge RC, Schmults CD, Clark RA, Kupper TS, Freeman GJ, Mackay LK, Naik S, Newell EW, Elemento O, Suarez-Farinas M, Anandasabapathy N. PD-1 is requisite for skin TRM cell formation and specification by TGFß. Nat Immunol. 2025 Aug; 26(8):1339-1351.
-
Milhem MM, Wise-Draper TM, Chandra S, Hanna GJ, Laux DE, Medina TM, Ansstas G, Daud A, Kelly CM, O'Day SJ, Perez CA, Wong MK, Friedlander PA, Kristedja TS, Burgess MA, Cowey CL, Hanks BA, Weight RM, Daniel WL, Feltner DE, Mix S, Sindelar L, Bexon AS, Bexon MF, Michel RE, Bhatia S. Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors. J Immunother Cancer. 2025 Jul 25; 13(7).
-
Wilky BA, Julian KA, Maleddu A, Mailhot AC, Cartwright CR, Gao D, Moreno Tellez C, Kemp LE, Therrien NR, Chaudhry SS, Rytlewski JD, Brockman QR, Davila E, Elias AD. A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti-CTLA-4 Antibody) and Balstilimab (Anti-PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas. Clin Cancer Res. 2025 Jul 15; 31(14):2945-2956.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|